Marker Therapeutics Inc (MRKR)

[MDtoB22]

I’m in agreement with many of your aforementioned points, however I believe the $200M mixed shelf registration in June 2019 speaks volumes to the competence of current management. Peter Hoang hyped the Pancreatic Cancer data and there’s no telling me otherwise. Given that the data was premature and that of a small sample, perhaps it was never going to be the rocket ship that moved the share price up beyond historical highs. With that in mind, why the hell wouldn’t management raise at least SOME cash during the run up? In hindsight, it was the classic “sell the news” setup in which the company gained nothing from.

As you stated, the AML trial delay can’t be put 100% on Peter, but I think someone will eventually have to fall on the sword. Burning through a fiscal year’s worth off cash with no tangible results to date is inexcusable.